Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Feng Bi(Tianjin University of Traditional Chinese Medicine), Feng Chen(Washington University in St. Louis), Helong Zhang(Shanghai International Studies University), Zishu Wang(Bengbu Medical College), Shukui Qin(81th Hospital of PLA), Hongming Pan(Sir Run Run Shaw Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Yinying Lu(Chinese PLA General Hospital), Shanzhi Gu(Central South University), Yuxian Bai(Harbin Medical University), Xi Chen(National Taiwan University Hospital), Xiufeng Liu(Sichuan University), Zhendong Chen(Anhui Medical University), Aibing Xu(Nantong Tumor Hospital), Liqing Wu, Ping Yang(Kunming Medical University), Zhiqiang Meng(Fudan University Shanghai Cancer Center)
Journal of Clinical Oncology
May 20, 2020
10.1200/jco.2020.38.15_suppl.4506
Cited by 39

Related Papers

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775